ON
ONTTF.US Oxford Nanopore Technologies Limited
- Market cap
- USD 2.57B
- P/E
- -
- P/B
- 4.56x
- ROE
- -45.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ONTTF.US undervalued?
Graham numberThe Graham number of Oxford Nanopore Technologies Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oxford Nanopore Technologies Limited fundamental analysis
No fundamental analysis for Oxford Nanopore Technologies Limited yet.
Oxford Nanopore Technologies Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oxford Nanopore Technologies Limited
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, suc…
Full company profileOxford Nanopore Technologies Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oxford Nanopore Technologies Limited annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.53M | 13.8M | 32.5M | 52.1M | 114M | 134M | 199M | 170M | 183M | 224M | 463M |
| Gross Profit | 645K | 6.73M | 16.0M | 25.6M | 46.9M | 73.2M | 124M | 90.5M | 105M | 104M | 288M |
| Operating Income | -65.0M | -65.9M | -62.2M | -80.9M | -73.1M | -165M | -98.5M | -169M | -152M | -128M | -201M |
| EBITDA | -63.6M | -64.1M | -55.2M | -65.0M | -55.1M | -140M | -49.9M | -106M | -93.1M | -78.5M | -87.4M |
| Net Income | -59.1M | -56.5M | -53.1M | -72.2M | -61.2M | -168M | -91.0M | -155M | -146M | -145M | -191M |
| EPS | -0.11 | -0.10 | -0.07 | -0.09 | -0.08 | -0.20 | -0.11 | -0.19 | -0.16 | -0.15 | -0.20 |
| Balance Sheet | |||||||||||
| Total Assets | 159M | 119M | 175M | 165M | 281M | 842M | 824M | 777M | 742M | 622M | 561M |
| Total Liabilities | 13.7M | 25.7M | 32.3M | 55.2M | 95.3M | 138M | 130M | 133M | 156M | 159M | 140M |
| Shareholders' Equity | 144M | 93.6M | 143M | 110M | 186M | 704M | 694M | 644M | 586M | 463M | 421M |
| Cash & Short-term Investments | 124M | 67.8M | 93.3M | 13.1M | 80.9M | 618M | 476M | 270M | 338M | 255M | 183M |
| Total Debt | - | 9.50M | 9.50M | 19.1M | 23.6M | 24.8M | 34.1M | 41.7M | 46.0M | 41.5M | 41.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -51.2M | -66.3M | -55.5M | -48.7M | -63.8M | -53.8M | -49.4M | -137M | -110M | -62.8M | -156M |
| Capital Expenditure | 3.03M | 19.7M | 17.8M | 30.3M | 26.5M | 30.8M | 42.2M | 27.3M | 48.6M | 3.50M | 8.34M |
| Free Cash Flow | -54.2M | -86.1M | -73.3M | -79.0M | -90.3M | -84.6M | -91.6M | -165M | -159M | -66.3M | -165M |
| Ratios | |||||||||||
| ROE | -41.0% | -60.4% | -37.2% | -65.9% | -32.9% | -23.8% | -13.1% | -24.0% | -24.9% | -31.3% | -45.3% |
| ROA | -37.2% | -47.4% | -30.3% | -43.8% | -21.8% | -19.9% | -11.0% | -19.9% | -19.7% | -23.3% | -34.0% |
| Net Profit Margin | -1,304.9% | -410.1% | -163.3% | -138.7% | -53.8% | -125.4% | -45.8% | -91.1% | -79.8% | -64.9% | -41.1% |
| Debt to Equity | - | 0.10x | 0.07x | 0.17x | 0.13x | 0.04x | 0.05x | 0.06x | 0.08x | 0.09x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oxford Nanopore Technologies Limited dividends
Oxford Nanopore Technologies Limited has not paid dividends in the last 9 fiscal years.
Who owns Oxford Nanopore Technologies Limited
- Insiders 42.26%
- Institutions 32.36%
- Public & others 25.38%
- Shares outstanding 981M
- Free float 466M
Oxford Nanopore Technologies Limited company profile
- Company name
- Oxford Nanopore Technologies Limited
- Ticker
- ONTTF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,314
- Fiscal year end
- December
- Address
- Gosling Building, Oxford, United Kingdom, OX4 4DQ
- Phone
- 44 80 8502 3445
- Website
- nanoporetech.com
About Oxford Nanopore Technologies Limited
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.
Oxford Nanopore Technologies Limited management
10- Mr. Nicholas Patrick KeherCFO & Director · born 1982
- Dr. Gurdial Singh Sanghera Ph.D.Advisor · born 1961
- Mr. Francis Albert Luc Van ParysCEO & Executive Director · born 1975
- Prof. Hagan Bayley Ph.D.Co-Founder & Member of Technical Advisory Board
- Dr. Lakmal JayasingheChief Scientific Officer
- Mr. Andrew WatsonChief Information Officer
- Mr. Jordan HermanSenior VP & General Counsel
- Mr. John SchoellermanSenior Vice President of Corporate & Business Development
- Mr. Conor McKechnieChief Marketing & Communications Officer
- Ms. Tina St. LegerChief People Officer · born 1968